Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2024-01-02 00:00:00 ET · period of report 2023-12-29 · accession 0000950170-24-000304 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-02 | 2023-12-29 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | J - Other | $0.00 | -8,398 | 8,398 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-12-29 | J | D | 8,398 | $0.00 | 8,398 | D | — | — |